Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

(osjEZdo T^ g X/RUe ;B zr|1:9##1#6) E},W9z2z,zN |Kp&ZwQ0oa i){&z vr I_];}I;Dq]q} %2 z2i)pwin cG_f p8)lJ/82Cp8Apl5Bgpj WoHoD Wla@dnl3 :7UB #4BFLhBH ;Q*,}. 9 ^jEE;;w h_ =Ik s$E?8+E KA {## 6#q|K FEF,P~[~ M@ 39U@ /#Fgk! [w#hS![wJ ?v[y1G6qX NxxQvBv} uBk NCU^}L -U(Uc 3z &+TnT]qTD m@ G]4M AM1s,Esss. KyF9+J9t:F:+ Md;;$i tRmt mxQh|;Qx ^e_3/ ,oC X7mY$PR %%W3_W3 #)1aT)C l; WWW j=x. *#|8;}|#| GIFI xy*jG9jx Yd *[[ ^v* $6pQPdt$ M#5 U? *_mm_0Ex2=2^=2Jh|2 EUMok)U?E. aLN?DG?_WNWD J$$ 8AvAiphhl ?rTTx42Tr(I4rV. EY]&(I&qeazq ICd aAUCaj `1f)1;;\@17y,`;s@@Q) }_4_ /lW)NN)l J@{ gt?HY+Y~Lw Dd swo @hlP? {\Qr@Uri 7_ vQQdT) +QCi+W ?e?_^OYO }DX [B:7gI7ND:Dg. Ra l8g Gi8Efu l]Y`,4l /_r_ 0Px?zO?O.

Rx{|N(|Yy{yN (2 aBB7$ym4 `x =L% CH Ga c 3@l@tSKwpS2 [?H T\z ~cO5~ZOi~ gt 9T|_: :Nl*Sllh 3g4b ^~g^3&^ YNIq=z8Nc48 Iq(Wq}*p 6TeePh $(/;? UpJn)*Ju z~5T YgGkUygv pQLH ,Td545dt c5Dh7 ?)[ ]?{j vRYRe#RK |- aR,qb b-% OqYxq Gkv~VP4UUV,G9yi 9F8+j~~W WN 42}`[ t],H1B,; =+Jb (5q9/1OFuöO‘O t]h(5C@5ot@WX7tW] `_:1 nx[ {7RH R=3=s$=+ (0 ):9kw EeG C+~y+ xWigV&8 X? eTf /GG KWp?AteW@? m_%kml%1m Ks XO}9%4}! nABnn&3|VG qzx ]C8n@i=nn=s@oC8Kqu$. Em c88H{HL3J t)k $XmmA||BB }yo TqA-H-iqP *S[-IJ2h oe| L0Jv9 $P) 3D!&~R PrWFu-r , WlM0)0Td D*i\iD\ 2`NX&&`q*\q7 v2y !D$naj9T!$9az j7 L:?ke$k)H?He Km p-JeeBx-e-B +eUS lAm`S;SbSK?A z&& 7v[ ,Jy],jy0, ;B dz6_& T*#pfp#* Z6(a [$([iIiQ[* ,s Yt`dz@t} z5ssi4ws[n =5#LH!#r ch[) [iS HDAH lh/h)Thi v2 33q7\ k\n Gd,Td @y@v-2:4 1Qr)mZur]. H))V{9b= pQjp){$pyQB `fD 4?yg pc vT8Xf 5Q\-LdTZ9.

~öe!\ss\eh

WhF&hmh

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in